ccRCC poses a challenge to known standards in cancer immunology because of the modest mutation burden; however, it responds to immunotherapies, and a higher CD8+ T cell infiltration has traditionally been linked to poor prognosis [39, 40]. Here, CD8A is linked to cancer.